However, in clinical studies, the combined treatment of patients with IDO1 and PD-L1 inhibitors did not significantly improve the outcome of the disease, whereas single treatment with the IDO1 inhibitor demonstrated minimal effects compared to those noted in the placebo group, in various tumor types including cervical cancer21. Here, IDO1 is linked to neoplasm.